Search research articles
Contact Us
Filters
Showing results (101-110 of 169) with videos related to
Page
of 17
Sort By:
Genomics
|
February 4, 2015
Rescue of gene-expression changes in an induced mouse model of spinal muscular atrophy by an antisense oligonucleotide that promotes inclusion of SMN2 exon 7
John F Staropoli, Huo Li, Seung J Chun, et al.
EMBO Molecular Medicine
|
September 10, 2013
Pathological impact of SMN2 mis-splicing in adult SMA mice
Kentaro Sahashi, Karen K Y Ling, Yimin Hua, et al.
Nucleic Acids Research
|
August 22, 2013
Rational design of antisense oligonucleotides targeting single nucleotide polymorphisms for potent and allele selective suppression of mutant Huntingtin in the CNS
Michael E Østergaard, Amber L Southwell, Holly Kordasiewicz, et al.
Biochemistry
|
October 30, 2010
Allele-selective inhibition of mutant huntingtin expression with antisense oligonucleotides targeting the expanded CAG repeat
Keith T Gagnon, Hannah M Pendergraff, Glen F Deleavey, et al.
Neuron
|
April 19, 2014
Muscle expression of mutant androgen receptor accounts for systemic and motor neuron disease phenotypes in spinal and bulbar muscular atrophy
Constanza J Cortes, Shuo-Chien Ling, Ling T Guo, et al.
Molecular Cell
|
August 28, 2010
The nuclear-retained noncoding RNA MALAT1 regulates alternative splicing by modulating SR splicing factor phosphorylation
Vidisha Tripathi, Jonathan D Ellis, Zhen Shen, et al.
Nature Communications
|
December 23, 2020
MaTAR25 lncRNA regulates the Tensin1 gene to impact breast cancer progression
Kung-Chi Chang, Sarah D Diermeier, Allen T Yu, et al.
The Journal of Pharmacology and Experimental Therapeutics
|
September 3, 2015
Identification and characterization of modified antisense oligonucleotides targeting DMPK in mice and nonhuman primates for the treatment of myotonic dystrophy type 1
Sanjay K Pandey, Thurman M Wheeler, Samantha L Justice, et al.
The Journal of Clinical Investigation
|
August 1, 2006
Antisense oligonucleotide therapy for neurodegenerative disease
Richard A Smith, Timothy M Miller, Koji Yamanaka, et al.
Parkinsonism & Related Disorders
|
August 19, 2015
Chronic and acute LRRK2 silencing has no long-term behavioral effects, whereas wild-type and mutant LRRK2 overexpression induce motor and cognitive deficits and altered regulation of dopamine release
Mattia Volta, Stefano Cataldi, Dayne Beccano-Kelly, et al.
Page
of 17
Search research articles
Search
Showing results (101-110 of 169) with videos related to
Sort By:
Page
of 17
Genomics
|
February 4, 2015
Rescue of gene-expression changes in an induced mouse model of spinal muscular atrophy by an antisense oligonucleotide that promotes inclusion of SMN2 exon 7
John F Staropoli, Huo Li, Seung J Chun, et al.
EMBO Molecular Medicine
|
September 10, 2013
Pathological impact of SMN2 mis-splicing in adult SMA mice
Kentaro Sahashi, Karen K Y Ling, Yimin Hua, et al.
Nucleic Acids Research
|
August 22, 2013
Rational design of antisense oligonucleotides targeting single nucleotide polymorphisms for potent and allele selective suppression of mutant Huntingtin in the CNS
Michael E Østergaard, Amber L Southwell, Holly Kordasiewicz, et al.
Biochemistry
|
October 30, 2010
Allele-selective inhibition of mutant huntingtin expression with antisense oligonucleotides targeting the expanded CAG repeat
Keith T Gagnon, Hannah M Pendergraff, Glen F Deleavey, et al.
Neuron
|
April 19, 2014
Muscle expression of mutant androgen receptor accounts for systemic and motor neuron disease phenotypes in spinal and bulbar muscular atrophy
Constanza J Cortes, Shuo-Chien Ling, Ling T Guo, et al.
Molecular Cell
|
August 28, 2010
The nuclear-retained noncoding RNA MALAT1 regulates alternative splicing by modulating SR splicing factor phosphorylation
Vidisha Tripathi, Jonathan D Ellis, Zhen Shen, et al.
Nature Communications
|
December 23, 2020
MaTAR25 lncRNA regulates the Tensin1 gene to impact breast cancer progression
Kung-Chi Chang, Sarah D Diermeier, Allen T Yu, et al.
The Journal of Pharmacology and Experimental Therapeutics
|
September 3, 2015
Identification and characterization of modified antisense oligonucleotides targeting DMPK in mice and nonhuman primates for the treatment of myotonic dystrophy type 1
Sanjay K Pandey, Thurman M Wheeler, Samantha L Justice, et al.
The Journal of Clinical Investigation
|
August 1, 2006
Antisense oligonucleotide therapy for neurodegenerative disease
Richard A Smith, Timothy M Miller, Koji Yamanaka, et al.
Parkinsonism & Related Disorders
|
August 19, 2015
Chronic and acute LRRK2 silencing has no long-term behavioral effects, whereas wild-type and mutant LRRK2 overexpression induce motor and cognitive deficits and altered regulation of dopamine release
Mattia Volta, Stefano Cataldi, Dayne Beccano-Kelly, et al.
Page
of 17